ProfileGDS5678 / 1419835_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 93% 92% 94% 88% 94% 92% 91% 95% 95% 93% 95% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9738994
GSM967853U87-EV human glioblastoma xenograft - Control 27.8805293
GSM967854U87-EV human glioblastoma xenograft - Control 37.8123893
GSM967855U87-EV human glioblastoma xenograft - Control 47.8947892
GSM967856U87-EV human glioblastoma xenograft - Control 58.0988494
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5821788
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7971494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.5484492
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.3956291
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.3922795
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.4124195
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9656993
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.53995
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.0289494